The importance of antiandrogen in prostate cancer treatment

Camille Lanz, Mostefa Bennamoun, Petr Macek, Xavier Cathelineau, Rafael Sanchez-Salas


Since 2011, Docetaxel is no longer the exclusive treatment for castration-resistant prostate cancer (CRPC), with the emergence of a new generation of hormonal treatments (1-4). Although the first antiandrogens generation has shown clinical benefit, their low affinity for the androgen receptor (AR) allows for the 5% to 10% of free dihydrotestosterone in the prostate to activate the AR (1).